Establishment Labs Adds M&A Veteran Taylor Harris to Board
Event summary
- Establishment Labs appointed Taylor Harris to its Board of Directors on June 29, 2026.
- Harris brings over 25 years of experience in corporate finance and executive leadership in healthcare and medical technology.
- He previously served as CEO of Cutera, Inc. and CFO of MyoKardia, which was acquired by Bristol Myers Squibb for $13.1 billion.
The big picture
Establishment Labs is bolstering its board with M&A and executive leadership expertise amid a competitive landscape in medical aesthetics. Harris's background in high-value acquisitions suggests the company may be positioning itself for further consolidation or strategic partnerships to drive growth. His addition underscores a focus on sustained innovation and shareholder value creation, critical as the firm aims to expand its global footprint.
What we're watching
- M&A Strategy
- Whether Harris's expertise will accelerate Establishment Labs' growth through strategic acquisitions.
- Board Dynamics
- How his leadership experience will influence the company’s long-term strategy and shareholder value creation.
- Market Positioning
- The pace at which Establishment Labs can solidify its position as a leader in the global aesthetics market.